Research programme: hepatitis C therapeutics - Enanta

Drug Profile

Research programme: hepatitis C therapeutics - Enanta

Alternative Names: EP-CyP212; EP-NS5A25; HCV cyclophilin binders - Enanta; HCV NS5A protein inhibitors - Enanta/Novartis; HCV polymerase inhibitors - Enanta; Tetrazole type hepatitis C serine protease inhibitors - Enanta

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Small molecules; Tetrazoles
  • Mechanism of Action Cyclophilin inhibitors; Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 06 Feb 2015 Preclinical candidate selection is ongoing in USA
  • 01 Oct 2014 NS5A inhibitors are no longer licensed to Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top